{"id":"NCT02471144","sponsor":"Novartis Pharmaceuticals","briefTitle":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","officialTitle":"A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-29","primaryCompletion":"2018-12-13","completion":"2023-03-30","firstPosted":"2015-06-15","resultsPosted":"2021-08-16","lastUpdate":"2023-10-11"},"enrollment":162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Severe Plaque-type Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Experimental : Secukinumab low dose","otherNames":["AIN457 low dose"]},{"type":"BIOLOGICAL","name":"Experimental: Secukinumab high dose","otherNames":["AIN457 high dose"]},{"type":"BIOLOGICAL","name":"Placebo Comparator: Secukinumab Placebo","otherNames":["AIN457 placebo"]},{"type":"BIOLOGICAL","name":"Active Comparator: Etanercept","otherNames":["Etanercept"]}],"arms":[{"label":"Secukinumab low dose","type":"EXPERIMENTAL"},{"label":"Secukinumab high dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Etanercept Comparator","type":"ACTIVE_COMPARATOR"}],"summary":"This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to \\<18 years were enrolled, of which at least 30 were 6 years to \\<12 years old. Subjects were enrolled at approximately 70 study sites worldwide.","primaryOutcome":{"measure":"Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12","timeFrame":"12 weeks","effectByArm":[{"arm":"AIN457 Low Dose","deltaMin":32,"sd":null},{"arm":"AIN457 High Dose","deltaMin":31,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null},{"arm":"Etanercept","deltaMin":26,"sd":null}],"pValues":[{"comp":"OG000","p":"<.0001"},{"comp":"OG001","p":"<.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":46,"countries":["United States","Belgium","Colombia","Egypt","Estonia","France","Germany","Guatemala","Hungary","Israel","Italy","Japan","Latvia","Poland","Romania","Russia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["37341961","36971771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":56},"commonTop":["Nasopharyngitis","Headache","Pharyngitis","Tonsillitis","Diarrhoea"]}}